We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 26 investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £340,928
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go: Expired investment: £274,530
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
Endlesss is a cloud-connected mobile and desktop app that turns music creation into a live, collaborative social event where musicians and fans can interact in real-time from anywhere in the world. The company argues that despite users making music, sharing that piece of music is a long and lonely process that takes days or months, requires multiple different apps and services, and carries no guarantee on whether those songs would be heard or not. Endlesss aims to change this via its software. The company witnessed over 9,000 sign-ups in May 2021, oversaw over 40,000 jams and 2.6 million riffs being created in 2020, and has spread across 100+ countries. Endlesss aspires to dominate the music creation software market that is expected to grow to $1.86 billion by 2027, up from $884 million in 2020. The company has received acclaim from entities such as Verge, TechCrunch and Pitchfork. Endlesss states it will use the investment to grow its team, develop new features, boost marketing, and promote Research & Development (R&D) to grow its business.
days to go: Expired investment: £415,541
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.

Pitch Rated

60%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £891,790
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph